What are Summit Therapeutics's total assets?

Summit Therapeutics (SMMT) holds $647.9M in total assets, up 68.8% year over year.

How much debt does Summit Therapeutics have?

Summit Therapeutics carries $20.0M in total debt against $545.9M of shareholders' equity, a debt-to-equity ratio of 0.04.

How much cash does Summit Therapeutics have?

Summit Therapeutics holds $8.2M in cash and equivalents.

Can Summit Therapeutics cover its short-term obligations?

Its current ratio is 7.41 — current assets exceed current liabilities.

Where does Summit Therapeutics's balance sheet data come from?

Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Summit Therapeutics SMMT Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$8.24M-49.7%	$16.37M+236%	$4.87M+14.2%	$4.27M-44.5%	$7.68M-52.8%
Short-term investments	$492.22M+0.8%	$488.18M—	$0—	$0-100%	$149.79M-51.3%
Restricted cash	$316K0.0%	$316K-1.6%	$321K+0.6%	$319K+0.3%	$318K-2.2%
Prepaid expenses and other current assets	$17.55M+168%	$6.54M-13.9%	$7.59M-31.3%	$11.05M+21.2%	$9.12M-17.7%
Total current assets	$616.6M-14.4%	$720.3M+192%	$246.47M-20.3%	$309.24M-16.6%	$370.75M-12.5%
Property and equipment, net	$1.66M+57.1%	$1.06M+30.7%	$810K+17.4%	$690K+5.8%	$652K+157%
Operating lease right-of-use assets	$19.4M-5.9%	$20.62M+280%	$5.42M-2.4%	$5.55M-12.6%	$6.35M-11.1%
Goodwill	$1.97M-1.8%	$2M+0.1%	$2M-2.0%	$2.04M+6.0%	$1.92M+3.2%
Other non-current assets	$8.23M+14.2%	$7.21M+2.4%	$7.03M+7.9%	$6.52M+57.2%	$4.15M+62.7%
Available-for-sale securities	$0—	$0—	$0—	$0—	$0—
Total assets	$647.86M-13.8%	$751.18M+187%	$261.73M-19.2%	$324.04M-15.6%	$383.82M-11.9%
Accounts payable	$27.55M+35.8%	$20.29M-8.8%	$22.25M-3.2%	$22.98M+360%	$4.99M+7.7%
Accrued expenses	$7.07M-52.6%	$14.93M+36.1%	$10.97M+66.3%	$6.59M+50.0%	$4.4M-63.3%
Operating lease liabilities, current	$3.18M-6.2%	$3.39M+24.6%	$2.72M-12.8%	$3.12M-12.0%	$3.54M-5.9%
Total current liabilities	$83.27M+14.1%	$72.99M+12.4%	$64.93M+7.6%	$60.33M+73.0%	$34.88M-16.4%
Operating lease liabilities, non-current	$16.86M-3.7%	$17.5M+546%	$2.71M+11.2%	$2.44M-16.2%	$2.91M-15.8%
Operating Lease Liabilities (Total)	——	$20.89M—	——	——	——
Other non-current liabilities	$1.8M-1.8%	$1.83M+0.1%	$1.83M-0.4%	$1.84M+7.6%	$1.71M+4.8%
Total liabilities	$101.92M+10.4%	$92.32M+32.9%	$69.47M+7.5%	$64.6M+63.6%	$39.49M-15.6%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	1B0.0%	1B0.0%	1B0.0%	1B0.0%	1B+13,457%
Additional paid-in capital	$3.02B+2.6%	$2.95B+30.3%	$2.26B+7.8%	$2.1B+29.7%	$1.62B+1.2%
Retained earnings	-$2.48B-8.3%	-$2.29B-10.6%	-$2.07B-12.6%	-$1.84B-44.3%	-$1.28B-5.2%
Accumulated other comprehensive income (loss)	-$2.63M-3.6%	-$2.54M+6.2%	-$2.71M+1.6%	-$2.75M-7.4%	-$2.56M-12.2%
Total stockholders' equity	$545.93M-17.1%	$658.86M+243%	$192.26M-25.9%	$259.44M-24.7%	$344.33M-11.4%
Total liabilities and stockholders' equity	$647.86M-13.8%	$751.18M+187%	$261.73M-19.2%	$324.04M-15.6%	$383.82M-11.9%
Deferred Tax Assets and Other Non-Current Assets	$8.23M+14.2%	$7.21M+2.4%	$7.03M+7.9%	$6.52M+57.2%	$4.15M+62.7%
Net Investment in Lease	$19.4M-5.9%	$20.62M+280%	$5.42M-2.4%	$5.55M-12.6%	$6.35M-11.1%
Operating lease right-of-use assets	$19.4M-5.9%	$20.62M+280%	$5.42M-2.4%	$5.55M-12.6%	$6.35M-11.1%
Other non-current assets	$8.23M+14.2%	$7.21M+2.4%	$7.03M+7.9%	$6.52M+57.2%	$4.15M+62.7%
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$492.22M+0.8%	$488.18M—	$0—	$0-100%	$149.79M-51.3%
Operating Lease Right-of-Use Assets in Other Assets	$19.4M-5.9%	$20.62M+280%	$5.42M-2.4%	$5.55M-12.6%	$6.35M-11.1%
Software and Technology Licenses, Net	$8.23M+14.2%	$7.21M+2.4%	$7.03M+7.9%	$6.52M+57.2%	$4.15M+62.7%
Accrued Manufacturing Costs	$7.07M-52.6%	$14.93M+36.1%	$10.97M+66.3%	$6.59M+50.0%	$4.4M-63.3%
Other Commercial Liabilities	$44.32M+38.1%	$32.1M+18.7%	$27.04M+3.4%	$26.15M+23.4%	$21.19M+8.3%
Accrued Liabilities, Current	$44.32M+38.1%	$32.1M+18.7%	$27.04M+3.4%	$26.15M+23.4%	$21.19M+8.3%
Compensation and benefits	$7.07M-52.6%	$14.93M+36.1%	$10.97M+66.3%	$6.59M+50.0%	$4.4M-63.3%
Other accrued liabilities	$1.15M-49.7%	$2.28M+16.7%	$1.96M+31.7%	$1.49M+95.7%	$759K-57.8%
Total debt	$20.04M-4.1%	$20.89M+285%	$5.43M-2.3%	$5.55M-13.9%	$6.45M-10.6%
Common Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common Stock Shares Issued	776M+0.1%	775.4M+4.2%	744.4M+0.2%	742.8M+0.2%	741.6M+0.5%
Convertible Preferred Stock Authorized Shares	20M0.0%	20M0.0%	20M0.0%	20M0.0%	20M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$7.76M+0.1%	$7.75M+4.2%	$7.44M+0.2%	$7.43M+0.2%	$7.42M+0.5%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Unrealized Gains on Investments	$0-100%	$172K—	$0—	$0—	$0-100%
Unrealized Losses on Investments (Before Tax)	$4K—	$0—	$0—	$0-100%	$33K—
Warrants and Rights Outstanding	0—	0—	0—	0-100%	1M-77.3%
Accrued research and development expenditure	$42.45M+34.8%	$31.5M+28.1%	$24.59M0.0%	$24.58M+32.0%	$18.63M+6.8%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$4K—	$0—	$0—	$0-100%	$33K—
Gross Unrealized Gains	$0-100%	$172K—	$0—	$0—	$0-100%
Class of Warrant or Right, Outstanding	$0—	$0—	$0—	$0-100%	$1.05M-77.3%
Common stock, par value (in dollars per share)	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	$1B0.0%	$1B0.0%	$1B0.0%	$1B0.0%	$1B0.0%
Common stock, shares issued (in shares)	$776.02M+0.1%	$775.37M+4.2%	$744.44M+0.2%	$742.81M+0.2%	$741.61M+0.5%
Common Stock, Shares, Outstanding	$776.02M+0.1%	$775.37M+4.2%	$744.44M+0.2%	$742.81M+0.2%	$741.61M+0.5%
Cost or Amortized Cost	$590.5M-15.3%	$696.91M+198%	$233.68M-20.4%	$293.61M-17.0%	$353.66M-10.7%
Available-for-sale securities, allowance for credit loss	$0—	$0—	$0—	$0—	$0—
Estimated Fair Value	$590.49M-15.3%	$697.08M+198%	$233.68M-20.4%	$293.61M-17.0%	$353.63M-10.7%
Preferred Stock, Par or Stated Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Preferred Stock, Shares Authorized	$20M0.0%	$20M0.0%	$20M0.0%	$20M0.0%	$20M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Prepaid research and development expenditures	$12.32M+208%	$4M-23.2%	$5.2M-36.2%	$8.16M+25.7%	$6.49M-22.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Summit Therapeutics's total assets?: Summit Therapeutics (SMMT) holds $647.9M in total assets, up 68.8% year over year.
How much debt does Summit Therapeutics have?: Summit Therapeutics carries $20.0M in total debt against $545.9M of shareholders' equity, a debt-to-equity ratio of 0.04.
How much cash does Summit Therapeutics have?: Summit Therapeutics holds $8.2M in cash and equivalents.
Can Summit Therapeutics cover its short-term obligations?: Its current ratio is 7.41 — current assets exceed current liabilities.
Where does Summit Therapeutics's balance sheet data come from?: Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.